Immunotherapy Targeting HER2-positive Breast Cancer
DOI:
https://doi.org/10.62051/z2t4ee06Keywords:
HER2-positive breast cancer; immunotherapy; monoclonal antibody; immune checkpoint inhibitor.Abstract
Breast cancer with HER2-positive status is highly invasive and susceptible to recurrence and metastasis, and its targeted immunotherapies mAb (e.g., trastuzumab, pertuzumab), ADCs (e.g., T-DM1, T-DXd), and ICIs have enhance the prognosis; however, their drug-resistance and adverse effects still limit their long-term efficacy. Despite advances in immunotherapy targeting HER2+, the indications for ICIs in HER2-positive breast cancer are unclear, the selection of biomarkers for combination therapy remains controversial. This article systematically summarizes several immunotherapeutic strategies for HER2-positive breast cancer and their research progress, including the mechanism of action,resistance management of mAb, the clinical advantages and toxicity risks of ADC , and the potential and challenges of ICI combination targeted therapy. Trastuzumab plus pertuzumab combination chemotherapy can enhance the survival of early-stage patients, while T-DM1 demonstrates safety advantages in drug-resistant second-line therapy; ICI combined with targeted therapy has preliminary efficacy in PD-L1-positive patients, and the specific applicability of the population needs to be further screened. This review provides a theoretical basis for optimizing the precision treatment of HER2-positive breast cancer, and in the future, in-depth exploration of drug resistance mechanisms, development of novel ADC, and combination therapy strategies based on the immune microenvironment are needed to break through the bottleneck.
Downloads
References
[1] Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res, 2014, 79: 34-74. DOI: https://doi.org/10.1016/j.phrs.2013.11.002
[2] Cho H S, Mason K, Ramyar K X, Stanley A M, Gabelli S B, Denney D W Jr, Leahy D J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421 (6924): 756-760. DOI: https://doi.org/10.1038/nature01392
[3] Maadi H, Soheilifar M H, Choi W S, Moshtaghian A, Wang Z. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers (Basel), 2021, 13 (14): 3540. DOI: https://doi.org/10.3390/cancers13143540
[4] Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J L, Pedersen K, Smith D J, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 2009, 28 (6): 803-814. DOI: https://doi.org/10.1038/onc.2008.432
[5] Molina M A, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 2001, 61 (12): 4744-4749.
[6] Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers (Basel), 2018, 10 (10): 342. DOI: https://doi.org/10.3390/cancers10100342
[7] Gianni L, Pienkowski T, Im Y H, Roman L, Tseng L M, Liu M C, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im S A, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13 (1): 25-32. DOI: https://doi.org/10.1016/S1470-2045(11)70336-9
[8] Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo J H, Tsai Y F, Ratnayake J, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013, 24 (9): 2278-2284. DOI: https://doi.org/10.1093/annonc/mdt182
[9] Advani P P, Ballman K V, Dockter T J, Colon-Otero G, Perez E A. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol, 2016, 34 (6): 581-587. DOI: https://doi.org/10.1200/JCO.2015.61.8413
[10] von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med, 2017, 377 (2): 122-131. DOI: https://doi.org/10.1056/NEJMoa1703643
[11] Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med, 2020, 30 (1): 22-28. DOI: https://doi.org/10.1016/j.tcm.2019.01.006
[12] Calabrich A, Fernandes Gdos S, Katz A. Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncology (Williston Park), 2008, 22 (11): 1250-1258.
[13] Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol, 2016, 10 (Suppl 1): 21-30. DOI: https://doi.org/10.4137/CMO.S34537
[14] Conilh L, Fournet G, Fourmaux E, Murcia A, Matera E L, Joseph B, Dumontet C, Viricel W. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals (Basel), 2021, 14 (3): 247. DOI: https://doi.org/10.3390/ph14030247
[15] Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop I E, Blackwell K, Hoersch S, Xu J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18 (6): 732-742. DOI: https://doi.org/10.1016/S1470-2045(17)30312-1
[16] Thon J N, Devine M T, Jurak Begonja A, Tibbitts J, Italiano J E Jr. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood, 2012, 120 (10): 1975-1984. DOI: https://doi.org/10.1182/blood-2012-04-420968
[17] Endo Y, Mohan N, Dokmanovic M, Wu W J. Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. Antib Ther, 2021, 4 (1): 55-59. DOI: https://doi.org/10.1093/abt/tbab005
[18] Liu K, Li Y H, Zhang X, Su L, Li J H, Shi H Y, Zhang J H. Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. Expert Rev Clin Pharmacol, 2022, 15 (11): 1343-1350. DOI: https://doi.org/10.1080/17512433.2022.2121704
[19] Hunter F W, Barker H R, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M J, Sotiriou C, Jamieson S M F. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer, 2020, 122 (5): 603-612. DOI: https://doi.org/10.1038/s41416-019-0635-y
[20] Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol, 2019, 20 (3): 371-382. DOI: https://doi.org/10.1016/S1470-2045(18)30812-X
[21] Emens L A, Esteva F J, Beresford M, Saura C, De Laurentiis M, Kim S B, Im S A, Wang Y, Salgado R, Mani A, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol, 2020, 21 (10): 1283-1295. DOI: https://doi.org/10.1016/S1470-2045(20)30465-4
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
